Jain Global’s Artiva Biotherapeutics ARTV Stock Holding History

Jain Global’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,171	Closed	-$25.9K	–	1594
2025 Q2	$25.9K	Buy	+17,171	New	+$36.1K	﹤0.01%	1126

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jain Global's ARTV Position: Q3 2025 in Review

Jain Global sold out of Artiva Biotherapeutics (ARTV) in Q3 2025, closing a stake of 17,171 shares — an estimated $25.9K sold.

Jain Global first reported a position in ARTV in Q2 2025 and held it in 1 quarter. The position peaked at $25.9K in Q2 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q3 2025.

Jain Global reported no remaining Artiva Biotherapeutics position as of Q3 2025 after selling out during the quarter.
Jain Global sold 17,171 Artiva Biotherapeutics shares in Q3 2025, an estimated $25.9K.
Jain Global first reported a position in Artiva Biotherapeutics in Q2 2025 and held it in 1 quarter.
Jain Global's Artiva Biotherapeutics position peaked at $25.9K in Q2 2025.
40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2025.

Based on Jain Global's 13F filing for Q3 2025, filed 14 Nov 2025.